+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline

  • ID: 4829192
  • Report
  • June 2019
  • Region: Global
  • 53 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline

Summary

The Systemic Lupus Erythematosus (SLE) pipeline is characterized by a high level of first-in-class innovation when compared to other therapy areas and the industry as a whole. Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While Systemic Lupus Erythematosus (SLE) can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN).

The high level of first-in-class innovation translates to numerous promising first-in-class targets with strong therapeutic potential. Of the total products in the Systemic Lupus Erythematosus (SLE) pipeline, 43% are first-in-class, indicating a high level of innovation.

There are currently 146 products in active development for Systemic Lupus Erythematosus (SLE). Around half of the pipelines are in early stage development, with 74 products in the discovery and preclinical stages. There are 50 first-in-class programs in the pipeline, acting on 48 first-in-class molecular targets.

Mark Needham, Pharma Analyst, says: “We have assessed all first-in-class molecular targets in the Systemic Lupus Erythematosus (SLE) pipeline and ranked them based on the commercial potential. We found non receptor tyrosine protein kinase, also known as tyrosine kinase 2 (TYK2) to have the highest potential. TYK2 is a key component of the IFN-1 signaling pathway, which is increasingly recognized as a central pathogenic mediator in Systemic Lupus Erythematosus (SLE). Other first-in-class targets with strong therapeutic potential include those targeting the complement system and adaptive signaling.

Needham adds: “Programs targeting cell surface antigens are prominent, comprising 12% of the pipeline. The remainder is made up of smaller target families, such as complement/adaptive immunity, neurotransmitters and receptors, and hormones and receptors.

The recent report "Systemic Lupus Erythematosus: Programs Targeting Cytokine and Growth Factor Signaling Dominate First-in-Class Pipeline", helps in understanding the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. It also helps in visualizing the composition of the Systemic Lupus Erythematosus (SLE) market in terms of dominant molecule types and molecular targets.

Scope
  • There are 146 pipeline programs in active development for SLE. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class SLE pipeline? Which first-in-class targets have been identified as most promising for the treatment of SLE? How does the distribution of target classes differ in terms of development stage?
  • Across the SLE landscape, there are 112 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?
Reasons to Buy
  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SLE market in terms of dominant molecule types and molecular targets.
  • Analyze and compare the SLE pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class pipeline products for SLE that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SLE products.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 SLE: Executive Summary
2.1 Pipeline Holds Potential for the Approval of More Targeted Therapies
2.2 High Levels of First-in-Class Innovation
2.3 High Unmet Need Remains for Disease-Modifying Pharmacotherapies

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in SLE
4.4 Epidemiology for SLE
4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between SLE Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Non Receptor Tyrosine Protein Kinase
6.3 Pipeline Programs Targeting Complement C3
6.4 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5
6.5 Pipeline Programs Targeting Cyclic GMP-AMP Synthase
6.6 Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta
6.7 Pipeline Programs Targeting Interleukin 1 Receptor Associated Kinase 1
6.8 Pipeline Programs Targeting Mannan-Binding Lectin Serine Protease 2
6.9 Pipeline Programs Targeting Toll-Like Receptor 8

7 Key Players and Deals
7.1 Overview

8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 About the Authors
8.5 About the Author
8.6 Contact Us
8.7 Disclaimer

List of Tables
Table 1: SLE Criteria
Table 2: SLE Diagnosed Prevalent Cases, millions (N), 2015-2025

List of Figures
Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Integrated Hypothesis for the Pathogenesis of SLE
Figure 3: SLE, Global Market by Molecule Type and Molecular Target, 2019
Figure 4: SLE, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 5: SLE, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 6: SLE, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 7: SLE, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 8: SLE, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 9: SLE, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll